Al-Marsoummi, S., Singhal, S., Garrett, S. H., Somji, S., Sens, D. A., & Singhal, S. K. (2025). CD133+CD24+ Renal Tubular Progenitor Cells Drive Hypoxic Injury Recovery via Hypoxia-Inducible Factor-1A and Epidermal Growth Factor Receptor Expression. International Journal of Molecular Sciences, 26(6), 2472. https://doi.org/10.3390/ijms26062472

Saha, N., Lee, S. G., Brockmann, E.-C., de la Cruz, M. J., Goldgur, Y., Mendoza, R. P., Stanchina, E. de, Love, T. M., Marvald, J., Xu, Y., Xu, K., Himanen, J. P., Lamminmäki, U., Veach, D., & Nikolov, D. B. (2024). Fully human monoclonal antibody targeting the cysteine-rich substrate-interacting region of ADAM17 on cancer cells. Biomedicine & Pharmacotherapy, 180, 117605. https://doi.org/10.1016/j.biopha.2024.117605

Spira, A., Girard, N., Krebs, M., Park, K., Shu, C., Dougherty, L., & Cho, B. C. (2023). A plain language summary of the results from the group of patients in the CHRYSALIS study with EGFR exon 20 insertion-mutated non-small-cell lung cancer who received amivantamab. Future Oncology, 19(33), 2213–2225. https://doi.org/10.2217/fon-2023-0284

Park, K., Haura, E. B., Leighl, N. B., Mitchell, P., Shu, C. A., Girard, N., Viteri, S., Han, J.-Y., Kim, S.-W., Lee, C. K., Sabari, J. K., Spira, A. I., Yang, T.-Y., Kim, D.-W., Lee, K. H., Sanborn, R. E., Trigo, J., Goto, K., Lee, J.-S., … Cho, B. C. (2021). Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. Journal of Clinical Oncology, 39(30), 3391–3402. https://doi.org/10.1200/jco.21.00662